Cohance Lifesciences Limited has issued a formal statement addressing the recent surge in trading volume of its equity shares. The company confirmed that there is no undisclosed information or material events that could account for the heightened activity. Management maintains that the current market movement is entirely driven by external market conditions and represents normal trading behavior rather than any internal corporate development.
Market Activity Statement
On April 13, 2026, Cohance Lifesciences provided a market update in response to queries regarding a significant increase in the trading volume of its scrip. The company stated that it has consistently fulfilled its obligations to communicate all material events to the exchanges.
Management Perspective
The leadership at Cohance Lifesciences emphasized that there is no pending information or hidden announcements that would influence the stock’s price or volume behavior at this time. The company’s official stance is that the recent fluctuations are purely market-driven and attributable to broader market conditions rather than any company-specific developments.
Commitment to Transparency
Cohance Lifesciences, formerly known as Suven Pharmaceuticals Limited, reaffirmed its commitment to maintaining transparency with its stakeholders. The company continues to monitor market activity and will continue to notify the public of any developments that qualify as sensitive information as and when such events occur.
Source: BSE
